Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib
We make recommendations based on 15 years of experience in using ruxolitinib and other JAK inhibitors for the treatment of myelofibrosis. We discuss when allogeneic haematopoietic stem cell transplantation (AHSCT) should be considered and some of the currently available alternative JAK inhibitors and trial options when AHSCT is not an option.
Authors
- Liesl Butler (ORCID: https://orcid.org/0000-0003-3720-6494)
- Claire Harrison
- Andrew C. Perkins (ORCID: https://orcid.org/0000-0003-3644-7093)
- Cecily J. Forsyth (ORCID: https://orcid.org/0000-0002-9108-3088)
Institutions
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Gosford Hospital (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- eJHaem
- Published
- 2025-03-21
- DOI
- https://doi.org/10.1002/jha2.70007
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council
- Cancer Council Victoria